Botulinum Toxin Pills

The intrinsic stability of preparations refers to the ability of botulinum toxin pills to maintain their structural integrity and biological activity during production, processing and storage, which mainly depends on the structural characteristics of toxin molecules and the compatibility of the formulation. From the perspective of molecular structure, BTX is composed of a heavy chain (H chain) and a light chain (L chain) connected by disulfide bonds.

The receptor-binding domain of the H chain and the protease active center of the L chain are the key structures maintaining its toxicity and therapeutic activity, and the conformational stability of these two regions directly determines the toxin activity.During the production process, parameters such as temperature and pressure in processes such as extraction and purification, tableting, and coating can all affect the integrity of disulfide bonds. If the process parameters are out of control, it is easy to cause denaturation and inactivation of toxin molecules.

The compatibility of the formulation is another key factor affecting intrinsic stability. Excipients added in oral preparations, such as enteric coating materials, absorption enhancers, fillers, and antioxidants, may destroy the structural stability of toxin molecules if they interact with toxin molecules. For example, some surfactant-based absorption enhancers may cause depolymerization of toxin molecules, while metal ions in fillers may catalyze the breakage of disulfide bonds.In addition, factors such as temperature, humidity, light, and oxygen content in the storage environment also significantly affect the stability of the preparation.

High temperature and high humidity environments will accelerate the oxidative degradation and moisture absorption denaturation of the toxin, while light may damage the polypeptide chain structure of the toxin through photooxidation.Preclinical research data show that the activity retention rate of unoptimized oral BTX preparations stored at room temperature for 3 months is less than 50%, while the activity retention rate stored for 6 months under the conditions of refrigeration at 2-8°C, sealed and protected from light can be increased to more than 80%, which fully proves the important impact of the storage environment on the intrinsic stability of the preparation.

Gastrointestinal environmental stability is a key prerequisite for botulinum toxin pills to reach target tissues and exert their effects, and its core is to resist the dual damage of gastric acid environment and intestinal enzymatic system. The strong acidic environment in the stomach (pH 1.5-3.5) will change the conformation of toxin molecules through protonation, destroy the receptor-binding domain structure of the H chain, and may catalyze the breakage of disulfide bonds, leading to exposure and inactivation of the toxin's active center.

In addition, pepsin in the stomach can specifically hydrolyze the peptide bonds in the toxin polypeptide chain, degrading it into inactive small molecular fragments.After entering the small intestine, the further action of intestinal proteases such as trypsin and chymotrypsin will aggravate the degradation of toxin molecules. Without effective protective measures, most of the oral toxin will lose its activity before reaching the intestinal mucosal absorption site.

There are significant differences in the tolerance of different serotypes of BTX to the gastrointestinal environment, which is also an important factor affecting the stability of the preparation. Among them, the H chain structure of type A BTX is relatively stable, and its tolerance to gastric acid and proteases is better than that of other serotypes such as type B and E. After incubation in a simulated gastric environment for 2 hours, the activity retention rate of type A BTX is about 30%, while that of type B BTX is less than 10%.

At present, enteric coating technology is mainly used in research and development to improve gastrointestinal environmental stability. Enteric coating materials can remain intact in the acidic environment of the stomach and only start to disintegrate when entering the small intestinal environment with pH above 5.5, thereby avoiding direct exposure of the toxin to the acidic environment and pepsin in the stomach. Some preparations also add enzyme inhibitors (such as aprotinin) as excipients to inhibit the degradation of toxins by intestinal proteases and further improve the activity retention rate in the gastrointestinal environment.

In vivo transport stability refers to the ability of BTX to maintain activity during transport to the nerve endings of target tissues after being absorbed by the intestinal mucosa into the blood circulation. Its core influencing factors include the effect of the blood environment and the metabolic clearance rate of the toxin. After entering the blood circulation, toxin molecules need to face multiple challenges such as plasma protein binding and plasma protease degradation.

Some toxin molecules will bind to plasma proteins such as albumin to form bound toxins. Although the binding process can protect the toxin from plasma protease degradation to a certain extent, bound toxins cannot penetrate the capillary wall to reach target tissues, and only free toxins have biological activity. At the same time, various proteases present in the blood may still degrade free toxins, leading to loss of activity.

The biotransformation of the liver is another important factor affecting in vivo transport stability. Toxin molecules entering the liver will be degraded into small molecular peptides or amino acids by proteases in hepatocytes. These degradation products completely lose their biological activity and can no longer exert the effect of blocking nerve conduction. Preclinical studies have shown that the elimination half-life of botulinum toxin pills is about 12-24 hours, which is significantly shorter than that of the injectable dosage form.This difference is largely due to the faster activity decay rate of the oral preparation during in vivo transport. In addition, the metabolic and clearance capacity of patients with hepatic and renal insufficiency decreases, which may lead to the accumulation of toxins in the body. However, the accumulated toxins are mostly inactive fragments, which may increase the risk of immune reactions in the body rather than enhance the therapeutic effect

Natural differences in stability exist among different serotypes of BTX due to structural differences, and this serotype-specific stability is the core basis for serotype selection in oral preparation development. In addition to the differences in gastrointestinal tolerance mentioned earlier, there are significant differences in the adaptability to preparation processes and storage stability among different serotypes of BTX.

For example, the polypeptide chain structure of type A BTX is tighter, and its tolerance to process parameters such as tableting pressure and coating temperature during production is stronger. Under the same process conditions, the activity retention rate of oral type A BTX preparations is 20%-30% higher than that of type E. Although type B BTX has slightly better penetration ability of the intestinal mucosa than type A, its structural stability is poor, and the activity decay rate during storage is faster, requiring stricter storage conditions.

Serotype-specific stability is also reflected in the compatibility between toxins and excipients. Type A BTX has good compatibility with commonly used enteric coating materials (such as hydroxypropyl methylcellulose phthalate) and absorption enhancers (such as bile salts), and will not cause structural denaturation due to interaction. In contrast, the activity of type D BTX mixed with some bile salt absorption enhancers will decrease by more than 40% within 24 hours.

Therefore, most of the current research and development of botulinum toxin pills take type A BTX as the core component, which is based on its relatively comprehensive stability advantages, making it easier to realize full-chain stability guarantee through formulation technology optimization.